AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03657355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.
Study NCT03657355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching-placebo will be used.
Study NCT01140321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neridronate
Description: Neridronate is an aminobisphosfonate of third generation that has been proved in several clinical trials to have the ability to inhibit osteoclast-mediated bone resorption and it is generally well tollerated also at high doses. Thanks to these properties it has been used in the treatment of several bone disorders such as Paget's disease and Osteogenesis Imperfecta. Neridronate, given intravenously or orally (tablets), reduces both the levels of bone alcaline phosphatase and of the other markers of bone resorption activity. Recently it has been approved by the Italian Ministry of Health for the commercialization with the indication Osteogenesis Imperfecta.
Study NCT02436278 — intervention group
Intervention type: OTHER
Intervention: 4MGS
Description: Usual walking speed measured over 4 metres
Study NCT01637974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INTERCOAT administration
Description: Applying INTERCOAT in the intrauterine cavity at the end of the hysteroscopic surgery
Study NCT00814086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV or intraperitoneally
Study NCT00814086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given intraperitoneally
Study NCT02154555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: debridement
Description: post-operative debridement at 1 week follow-up visit
Study NCT01045109 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 4,000 I.U. softgel daily orally for 48 weeks
Study NCT01045109 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: cholecalciferol or vitamin D3 4,000 IU daily for 48 weeks
Study NCT01611987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MStep
Description: Participant will meet with instructor twice to learn how to exercise safely. Exercises will be demonstrated and practiced under the direct supervision of the instructor. Written details and pictures will be made. Variety in exercise will be encouraged to promote long-term adherence. Stretching, strengthening and relaxation exercises will be given. Persons will be given Thera Band® to facilitate resistance exercise training and instructed how to progress. Equipment such as Nordic Walking Poles, stationary bicycle, BOSU®, or exercise balls will be available. Rather than having a fixed rigid prescription, the aim is to get people to intuitively adjust the amount of resistance so they feel they are working without causing harm, they are not doing the same boring activity, week in week out.
Study NCT01611987 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General guideline approach
Description: Individuals in the control condition will meet with the exercise instructor on two occasions during the first two weeks to review key components of public health guidelines for physical activity and health. In brief, the general guidelines for MS are (i) aerobic and endurance exercise for 30 minutes per session, 3 times per week at an intensity of 60% to 75% of heart rate peak; (ii) weight training for weak muscles, 2 days per week, on non-endurance days, 8 to 15 repetitions per exercise; and (iii) stretching daily with active or passive range of motion exercises, or attendance at Yoga or Tai Chi classes.
Study NCT03163888 — intervention group
Intervention type: PROCEDURE
Intervention: Navigation TKR
Description: Traditional over Conventional TKR
Study NCT02638285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH
Study NCT02638285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG
Study NCT02638285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Study NCT03996993 — intervention group
Intervention type: DRUG
Intervention: Casodex, Axumin
Description: Patients will receive hormone therapy if Axumin positive area appears.
Study NCT03996993 — intervention group
Intervention type: RADIATION
Intervention: Salvage Radiation, Axumin
Description: Patients will receive salvage radiation therapy if Axumin positive area appears.
Study NCT00050505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax undiluted. Cohort A receives undiluted dose of Dryvax vaccine
Study NCT00050505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.
Study NCT03464162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network Meetings
Description: Social Network Meetings are a type of family therapy that includes clients and members of their social network.The social network may include family members, friends or anyone else that clients believe can help them move toward recovery. The meetings will focus on improving communication within the social network.
Study NCT03464162 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Social Network Meetings
Description: Social Network Meetings are a type of family therapy that includes clients and members of their social network.The social network may include family members, friends or anyone else that clients believe can help them move toward recovery. The meetings will focus on improving communication within the social network.
Study NCT04589221 — intervention group
Intervention type: BEHAVIORAL
Intervention: Ad libitum energy intake
Description: Investigate ad libitum energy intake according to degree of food processing and eating behaviour
Study NCT00182793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Cycle 1: 6 mg/kg on day -2 from PBSC reinfusion Cycle 2: 6 mg/kg on day -7 from PBSC reinfusion
Study NCT00182793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Cycle 2: 800 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
Study NCT00182793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cycle 2: 6000 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
Study NCT00182793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Cycle 1: 150 mg/m2 on day -1 from PBSC reinfusion
Study NCT00182793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Cycle 2: 500 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
Study NCT00182793 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation and helical tomotherapy or loco-regional radiotherapy.
Study NCT00182793 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation
Description: Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation.
Study NCT00182793 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Description: Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation
Study NCT00182793 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: After recovery from high-dose chemotherapy and autologous PBSC transplantation; patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Treatment should be delivered daily M-F @ 180-200 cGY/day to a total of 4,500 to 5,040 cGy.~Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites. Treatment should be delivered daily @180-220 cGY/day to a total of 4,000-5,000 cGy.
Study NCT03349346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablet (s) or dispersible tablets for suspension administered orally twice daily
Study NCT03349346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously
Study NCT03349346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 3 mg/m\^2 administered intravenously
Study NCT03349346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 635 mg/m\^2 administered intravenously
Study NCT03349346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m\^2 administered intravenously
Study NCT01593046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 Oral
Description: 30mg tablet
Study NCT01593046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 LAP 800mg intramuscular injection
Description: 800mg Loading dose given at month 1 dose
Study NCT01593046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 LAP 200mg subcutaneous injection
Description: 200mg maintenance dose give at months 2 - 4
Study NCT01593046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 LAP 200mg intramuscular injection
Description: 200mg maintenance dose given at months 2 - 4
Study NCT01593046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 LAP 400mg intramuscular injection
Description: 400mg maintenance dose given at month 2 - 4
Study NCT01593046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278 LA 1200mg intramuscular injection
Description: 1200mg Loading dose given at month 3
Study NCT01593046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278 LA 600mg intramuscular injection
Description: 600mg Loading dose given at month 4
Study NCT01593046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 LAP 800mg intramuscular injection
Description: 800mg dose given quarterly (once every) 12 weeks
Study NCT02825589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIA
Description: BIA or bioelectrical impedance analysis using electric current through body tissues to estimate body composition particularly body fat and total body water calculating to target body weight.
Study NCT00694239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knowledge of Cardiovascular Risk Assessment
Description: Knowledge of Cardiovascular Risk Assessment and risk reduction at target BP, reviewed every 3-6 months.
Study NCT02330731 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: injection sclerotherapy for gastric varices
Description: The intravariceal technique of injection
Study NCT04130243 — intervention group
Intervention type: OTHER
Intervention: Blood test
Description: Withdrawal of (extra) blood to measure serum biomarkers with a blood test
Study NCT00727753 — intervention group
Intervention type: DRUG
Intervention: Ranibizumab
Description: ranibizumab (0.5 mg) will be injected intraocular
Study NCT01044108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0453
Description: Administration of a single subcutaneous (under the skin) dose. Up to 7 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
Study NCT00727753 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab (1.25 mg) will be injected intraocular
Study NCT00727753 — intervention group
Intervention type: OTHER
Intervention: No treatment
Description: No treatment
Study NCT03429179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol
Description: intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
Study NCT01180829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback text messages
Description: A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking.
Study NCT01180829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consciousness raising text messages
Description: A series of 12 text messages, each of which consists of an item designed to get the person to think about his or her drinking
Study NCT00114894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safe Sea ™
Description: Safe Sea ™ applied one time at 2 mg/cm2 coverage
Study NCT00114894 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo Coppertone® SPF15 sunscreen(Schering-Plough) applied at 2 mg/cm2 body coverage
Study NCT01044108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: '2-0453
Description: Administration of multiple subcutaneous (under the skin) doses for 10 weeks. Up to 4 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
Study NCT01044108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo will be administered as a comparator at each dose level.
Study NCT02176122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
Study NCT02176122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam combination product
Description: Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
Study NCT02993731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Napabucasin
Description: Napabucasin will be administered orally, twice daily, with doses separated by approximately 12 hours.
Study NCT02993731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
Study NCT02993731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
Study NCT03429179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: intravenous infusion of the same volume of 0.9% saline
Study NCT01405963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered in a 1-hour intravenous infusion
Study NCT02578329 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual low-fat dietary advice
Description: usual low-fat dietary advice for cardiovascular disease
Study NCT02993731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
Study NCT02993731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
Study NCT04749303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large Screen
Description: Large screen size is 4x larger than standard screen, we hope that the colonoscopies carried out with large screens will confer to better lesion detection
Study NCT00620685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, once daily for 4 weeks
Study NCT01493024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium silicate (ZS)
Description: Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated microporous Zirconium Silicate, an oral sorbent) administered 3 times daily (tid) with meals.
Study NCT01405963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Administered in a 1-hour intravenous infusion
Study NCT01493024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized to mimic escalating doses of experimental drug administered 3 times daily (tid) with meals.
Study NCT01333020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cross-linking of an emulsion drink
Description: This study will assess whether a subtle change in food structure (cross-linking of interfacial protein) can alter gastric emptying rate.
Study NCT03908658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle Training and Nasal High Flow
Description: Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Nasal High Flow will support respiratory muscles and thus reduce the work of breathing. By this mechanism the endurance of the respiratory muscles will increase in parallel with the strenght
Study NCT03908658 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training and Venturi mask
Description: Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Venturi mask is usually applied after extubation in every day clinical practice for oxygen supplementation
Study NCT02441387 — intervention group
Intervention type: DRUG
Intervention: Antidepressant
Description: Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.
Study NCT02441387 — intervention group
Intervention type: OTHER
Intervention: Psychoeducation
Description: Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment). The psychoeducation program consists of 10 individual sessions, conducted by a trained psychologist who will explain the main concepts of depression and its symptoms, the importance of adhering to treatment, the main side effects of pharmacological treatment, and how to cope with daily difficulties.
Study NCT02441387 — intervention group
Intervention type: OTHER
Intervention: Treatment as usual (only pharmacological treatment).
Description: Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment).
Study NCT00551681 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biventricular pacemaker with epicardial left ventricular lead
Description: epicardial left ventricular lead placement
Study NCT00551681 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transvenous left ventricular lead placement
Description: implantation of biventricular pacemaker with transvenous left ventricular lead placement
Study NCT03436576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Serum 20%
Description: Instillation of 1 drop of Autologous Serum 20% four times a day
Study NCT00620685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 1 mg PH-797804, once daily for 4 weeks
Study NCT00620685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 5 mg PH-797804, once daily for 4 weeks
Study NCT03428711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesoglycan Oral Tablet
Description: Experimental drug: mesoglycan, already used in the treatment of chronic venous ulcers, is a complex mucopolysaccharide, composed of a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~Used in oral formulation, hard capsules, 50 mg, twice-a-day, for 12 months. Reference therapy: placebo, organoleptically indistinguishable from the experimental drug, twice-a-day, for 12 months.
Study NCT03428711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Indistinguible placebo tablet
Study NCT00180011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: injectable medication
Study NCT00791596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic Intervention
Description: The intervention used in this investigation was an ergonomic adjustment of the VDT workstation design